Tiragolumab

Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT) . Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma[1][2][3][4].

Product Specifications

CAS Number

[1918185-84-8]

Product Name Alternative

MTIG-7192A; RG-6058

UNSPSC

12352203

Target

CD28

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tiragolumab.html

Purity

99.04

Solubility

H2O

Smiles

[Tiragolumab]

Molecular Weight

(148.66 kDa)

References & Citations

[1]Houssaini MS, et al. Advances in the management of non-small cell lung cancer (NSCLC) : A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239. |[2]Caruso C. Tiragolumab Impresses in Multiple Trials. Cancer Discov. 2020 Aug;10 (8) :1086-1087. |[3]Shen X, et al. TIGIT-Fc Promotes Antitumor Immunity. Cancer Immunol Res. 2021 Sep;9 (9) :1088-1097. |[4]Dai T, et al. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Sci Rep. 2024 May 9;14 (1) :10661.